YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Schrodinger, Inc. SDGR shares soared 7.6% in the last trading session to close at $32.6. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 50.9% gain over the pas…
Schrödinger (SDGR) has drawn fresh attention after recent trading left the share price at US$28.85, with the stock up strongly over the past month and past 3 months. Investors are reassessing what that move reflects. For context, Schröding…
Recursion Pharmaceuticals RXRX continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive…
Biotechnology and medical scientific research by Brian A Jackson via Shutterstock DataMEDS AI (MEDS) announced on Sept. 15 that it acquired Helomics and a lab services business, sparking a huge rally in MEDS stock. Shares of MEDS stock gai…
SOPHiA GENETICS SA SOPH shares rallied 7% in the last trading session to close at $8.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.…
NEW YORK, September 17, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company's common stock to thre…
Schrodinger, Inc. SDGR shares rallied 12.1% in the last trading session to close at $23.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's…
Tectora secures $55 million Series A investment from NEA and RA Capital Management NEW YORK, September 09, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
Recursion Pharmaceuticals RXRX uses an AI-driven drug discovery platform, Recursion Operating System (OS), to identify and develop novel therapies across its pipeline. It is advancing several clinical-stage programs, with REC-4881 emerging…
AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery ma…
NEW YORK, September 01, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will…
For Immediate Release Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial m…
Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most persistent challenges: lengthy timelines, high development costs and substantial clinical failure rates. Traditional drug d…
NEW YORK, August 14, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly…
Quick Read Tempus AI (TEM) hit five straight EPS beats with shares up 17%, as Twist Bioscience (TWST) logged 14 straight quarters of sequential revenue growth. Anthropic targets a September IPO with a healthcare AI pitch that could front-r…
In the past few days, Schrödinger, Inc. reported second-quarter 2026 results showing revenue of US$58.89 million and a shift to a US$5.98 million net profit, while also expanding its long-running collaboration with Bristol Myers Squibb to…
This article first appeared on GuruFocus. ACV: $29.6 million in Q2 2026, representing 27% year-over-year growth; ACV excluding contribution was $22.6 million, up 23%. Trailing Four-Quarter ACV: Reached $208 million; first half 2026 ACV of…
Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recur…
Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery NEW YORK, August 05, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today an…
NEW YORK, August 05, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. B…
Collaboration with NVIDIA and Google Cloud Provide Additional Tools and Compute Access NEW YORK, July 27, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new age…
NEW YORK, July 22, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and w…
NEW YORK, July 20, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company's common stock to four newly hir…
Quick Read AI cuts drug discovery from years to weeks, targeting a 10-15 year pipeline where 90% of candidates never reach market approval. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue, a gain of 215%, while No…
Senseonics Holdings SENS shares soared 6.1% in the last trading session to close at $5.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.8% loss over the p…
Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an "Equal Weight" rating on the shares. Sep…
Schrodinger Inc (NASDAQ:SDGR) is one of the best long-term stocks to invest in according to Bill & Melinda Gates Foundation Trust. The stock is backed by 31 hedge funds. Schrodinger shares are up around 13% over the past month, and analyst…
NEW YORK, June 18, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly h…
As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals(NASDAQ:RXRX) and Schrödinger(NASDAQ:SDGR) depends on whether you prefer a biotech-heavy or software-focused investment approach.…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing i…
NEW YORK, May 22, 2026--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired e…
Key Points Schrödinger combines AI-driven drug discovery with a real software revenue business. Sarepta focuses on gene therapy and is delivering solid sales despite ongoing regulatory concerns. NRX awaits upcoming FDA decisions and depres…
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billio…
Quick Read Dislocation between share price and product progress is exactly the kind of setup retail investors should scan for. Here are seven healthcare AI stocks trading under $50 where the bull case is grounded, not hype. The analyst who…
It's been a pretty great week for Schrödinger, Inc. (NASDAQ:SDGR) shareholders, with its shares surging 11% to US$13.28 in the week since its latest first-quarter results. Revenues came in 23% better than analyst models expected, at US$59m…